Vivos Therapeutics Inc. (VVOS): Price and Financial Metrics
GET POWR RATINGS... FREE!
VVOS Stock Summary
- VVOS has a market capitalization of $7,916,169 -- more than approximately only 3.29% of US stocks.
- With a one year PEG ratio of 0.42, VIVOS THERAPEUTICS INC is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than only 4.99% of US stocks.
- The volatility of VIVOS THERAPEUTICS INC's share price is greater than that of 92.55% US stocks with at least 200 days of trading history.
- Stocks that are quantitatively similar to VVOS, based on their financial statements, market capitalization, and price volatility, are RAVE, CURI, NVFY, BFRI, and LOPE.
- VVOS's SEC filings can be seen here. And to visit VIVOS THERAPEUTICS INC's official web site, go to www.vivoslife.com.
VVOS Valuation Summary
- In comparison to the median Healthcare stock, VVOS's price/earnings ratio is 101.29% lower, now standing at -0.3.
- VVOS's price/sales ratio has moved down 13.3 over the prior 28 months.
Below are key valuation metrics over time for VVOS.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| VVOS | 2023-03-24 | 0.5 | 0.8 | -0.3 | -0.2 |
| VVOS | 2023-03-23 | 0.5 | 0.8 | -0.3 | -0.2 |
| VVOS | 2023-03-22 | 0.5 | 0.8 | -0.3 | -0.2 |
| VVOS | 2023-03-21 | 0.5 | 0.8 | -0.3 | -0.2 |
| VVOS | 2023-03-20 | 0.5 | 0.8 | -0.3 | -0.1 |
| VVOS | 2023-03-17 | 0.5 | 0.8 | -0.3 | -0.2 |
VVOS's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- VVOS has a Quality Grade of D, ranking ahead of 23.33% of graded US stocks.
- VVOS's asset turnover comes in at 0.795 -- ranking 38th of 186 Medical Equipment stocks.
- 500 - Internal server error
The table below shows VVOS's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2020-12-31 | 0.795 | 0.797 | 5.192 |
| 2020-12-31 | 0.795 | 0.797 | 5.192 |
VVOS Price Target
For more insight on analysts targets of VVOS, see our VVOS price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $12.00 | Average Broker Recommendation | 1.5 (Moderate Buy) |
VVOS Stock Price Chart Interactive Chart >
VVOS Price/Volume Stats
| Current price | $0.33 | 52-week high | $2.96 |
| Prev. close | $0.32 | 52-week low | $0.30 |
| Day low | $0.32 | Volume | 106,800 |
| Day high | $0.34 | Avg. volume | 2,938,040 |
| 50-day MA | $0.76 | Dividend yield | N/A |
| 200-day MA | $0.93 | Market Cap | 8.26M |
Vivos Therapeutics Inc. (VVOS) Company Bio
Vivos Therapeutics, Inc., a medical technology company, engages in the development and commercialization of technology solutions for patients with sleep disordered breathing (SDB) comprising mild-to-moderate obstructive sleep apnea (OSA). The company's solutions cover proprietary alternatives for treating mild-to-moderate OSA; craniofacial and anatomical anomalies that are associated with mild-to-moderate OSA. Its treatment for OSA involves specially designed and customized oral appliances and treatment protocols. The company, through its Vivos Integrated Healthcare Network, provides access to healthcare providers for delivering care for patients suffering from sleep disordered breathing, including mild-to-moderate OSA. Vivos Therapeutics, Inc. also licenses its intellectual property to third-party manufacturers, which fabricate appliance devices for healthcare professionals. It caters to general dentists, medical doctors, myofunctional therapists, chiropractors, healthcare providers, and patients in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2007 and is based in Highlands Ranch, Colorado.
Latest VVOS News From Around the Web
Below are the latest news stories about VIVOS THERAPEUTICS INC that investors may wish to consider to help them evaluate VVOS as an investment opportunity.
Vivos Therapeutics to Participate in Fireside Chat at the 35th Annual ROTH ConferenceLITTLETON, Colo., March 08, 2023 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (the “Company” or “Vivos”) (NASDAQ:VVOS), a medical device and technology company that delivers training and a full line of highly effective proprietary oral appliances for the treatment of breathing related sleep disorders in adults, including mild-to-moderate obstructive sleep apnea (OSA) and snoring, today announced that Kirk Huntsman, Vivos’ Chairman and CEO and Brad Amman, CFO, will participate in a fireside chat |
Vivos Therapeutics Expands Product Line and Revenue Potential with Acquisition of Product Rights and Patents from Advanced Facialdontics, LLCAcquisition Adds Complementary, Lower Cost Products for Treating Conditions Associated with Obstructive Sleep ApneaLITTLETON, Colo., March 01, 2023 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (the “Company” or “Vivos”) (NASDAQ:VVOS), a medical device and technology company that delivers training and a full line of highly effective proprietary oral appliances for the treatment of breathing related sleep disorders, including mild-to-moderate obstructive sleep apnea (OSA) and snoring in adults, to |
Vivos Therapeutics to Present at the Emerging Growth Conference on February 22, 2023Chairman and CEO Kirk Huntsman to Present at 12:35 pm ETLITTLETON, Colo., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (the “Company” or “Vivos”) (NASDAQ:VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea (OSA) and snoring in adults, today announced that Kirk Huntsman, Vivos’ Chairman and Chief Executive Officer, will be present |
Presenting on the Emerging Growth Conference on February 22 Register NowMIAMI, Feb. 21, 2023 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 50th Emerging Growth Conference on February 22, 2023. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the conference here. Submit Questions for any of the presenting companie |
7 Micro-Cap Stocks to Buy for Risk-Taking InvestorsThese micro-cap stocks have tremendous growth potential and a history of big moves, but they also come with plenty of volatility. |
VVOS Price Returns
| 1-mo | -45.90% |
| 3-mo | -17.91% |
| 6-mo | -49.22% |
| 1-year | -87.55% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -17.91% |
| 2022 | -82.13% |
| 2021 | -61.93% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...